(Q48856213)

16 February 2018

title

Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. (English)

1 reference

16 February 2018

acute myocardial infarction

main subject

anti-retroviral agent

0 references

myocardial infarction

1 reference

based on heuristic

inferred from title

1 reference

1 reference

2

1 reference

16 February 2018

Pablo Tebas

5

1 reference

16 February 2018

author name string

Roger J Bedimo

1

1 reference

16 February 2018

Henning Drechsler

3

1 reference

16 February 2018

Gabriela Vidiella

4

1 reference

16 February 2018

language of work or name

English

0 references

publication date

1 July 2011

1 reference

16 February 2018

Clinical Infectious Diseases

published in

1 reference

16 February 2018

volume

53

1 reference

16 February 2018

issue

1

1 reference

16 February 2018

page(s)

84-91

1 reference

16 February 2018

Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

HIV infection in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Hepatitis C virus infection and increased risk of cerebrovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

The association between hepatitis C infection and prevalent cardiovascular disease among HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Chronic kidney disease predicts cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Kidney function and the risk of cardiovascular events in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

The Immunology Case Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Development and verification of a "virtual" cohort using the National VA Health Information System.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Endothelial markers and HIV infection in the era of highly active antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIR269

21 January 2018

Identifiers

DOI

10.1093/CID/CIR269

1 reference

16 February 2018

PubMed ID

21653308

1 reference

16 February 2018